Lutathera for Meningioma
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that treatment with Somatostatin LAR must be stopped 4 weeks before the trial, and short-acting Octreotide must be stopped for more than 24 hours before treatment. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Lutathera for treating meningioma?
Is Lutathera safe for human use?
How is the drug Lutathera different from other treatments for meningioma?
Lutathera is unique because it is a radiopharmaceutical therapy that uses a radioactive substance to target and treat tumors, specifically those with somatostatin receptors, which is different from traditional chemotherapy or surgery. It is administered intravenously and can be done on an outpatient basis, making it more convenient for patients.14567
What is the purpose of this trial?
This trial tests Lutathera, a targeted radiation therapy given through an IV, in patients with certain types of growing or high-risk brain tumors. The treatment aims to destroy tumor cells using targeted radiation.
Research Team
Erik Sulman, MD
Principal Investigator
New York Langone Health
Eligibility Criteria
Adults with progressive or high-risk meningioma who show positive uptake on PET-MRI scans and have tumors expressing SSTR2. Participants must be over 18, able to undergo regular MRI scans, have stable neurological symptoms for at least a month before joining, and good organ function. They should not be pregnant, breastfeeding, or have had certain other treatments like peptide receptor radionuclide therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Imaging
Ga-DOTATATE PET-MRI scans obtained prior to initiation and 6 months after initiation of Lutathera treatment
Treatment Details
Interventions
- Lutathera
Lutathera is already approved in United States, European Union for the following indications:
- Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults and pediatric patients 12 years and older
- Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor